Progressive relapsing multiple sclerosis

Summary

Progressive relapsing multiple sclerosis (MONDO:0000452) is a disease and 3 clinical trials. Top therapeutic interventions include corticotropin, teriflunomide, and tolebrutinib. A subtype of chronic progressive multiple sclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	progressive relapsing multiple sclerosis
Mondo ID	MONDO:0000452
DOID	DOID:0050785
SNOMED CT	230374002
UMLS	C0393666
MedGen	95982
Is cancer (heuristic)	no

Disease family

This is a subtype of chronic progressive multiple sclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › multiple sclerosis › chronic progressive multiple sclerosis › progressive relapsing multiple sclerosis

Related subtypes (2): secondary progressive multiple sclerosis, primary progressive multiple sclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06372145	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT01950234	PHASE2	TERMINATED	ACTH in Progressive Forms of MS
NCT00813969	PHASE1	COMPLETED	Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CORTICOTROPIN	4	1
TERIFLUNOMIDE	4	1
TOLEBRUTINIB	3	1